Kamada (KMDA)
(Delayed Data from NSDQ)
$5.24 USD
-0.13 (-2.42%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $5.25 +0.01 (0.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.24 USD
-0.13 (-2.42%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $5.25 +0.01 (0.19%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Sell Stocks for August 25th
by Zacks Equity Research
BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021
Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
by Zacks Equity Research
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases
by Zacks Equity Research
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children
by Zacks Equity Research
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
by Zacks Equity Research
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
Kamada (KMDA) Q1 Earnings Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Kamada (KMDA) Q4 Earnings Expected to Decline
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Consider Kamada (KMDA) Stock Now?
by Zacks Equity Research
Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.
Kamada (KMDA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Kamada (KMDA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS
3 Plasma Stocks to Win Big on FDA's Convalescent EUA
by Tirthankar Chakraborty
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Kamada (KMDA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
How Kamada (KMDA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kamada (KMDA) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day
by Zacks Equity Research
LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day